Dishman Carbogen Amcis profit and loss

Latest FY26

Revenue: ₹2,932cr+8.1% on FY25
EBITDA: ₹566cr+20.6% on FY25
Net profit: ₹97.5cr+2,907.7% on FY25
EPS: ₹6.22+2,861.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,901	2,932	2,712	2,616	2,413	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	49.4	55.9	21.7	28.2	27.8
	2,951	2,988	2,733	2,644	2,441
	427	488	593	601	625
	−2.0	−79.1	−91.3	−4.0	−114
	1,484	1,447	1,294	1,208	1,035
	169	174	159	120	85.7
	348	339	294	311	281
	507	511	447	524	534
	2,933	2,879	2,696	2,760	2,447
	485	566	469	287	332
	137	227	175	−24.4	51.5
Profit
	17.9	109	37.4	−116	−6.4
	−2.8	−3.8	−18.1	−6.1	−48.2
	15.0	105	19.3	−122	−54.6
	43.8	59.1	43.8	54.2	30.1
	−44.9	−51.6	−27.7	−23.0	−54.9
	−1.2	7.5	16.1	31.2	−24.8
	16.2	97.5	3.2	−153	−29.8
	16.2	97.5	3.2	−153	−29.8
	439	748	201	−28.8	291
	455	845	204	−182	261
	16.2	97.5	3.2	−153	−29.8
Per share
	₹1.03	₹6.22	₹0.21	−₹9.79	−₹1.90
	₹1.03	₹6.22	₹0.21	−₹9.79	−₹1.90
Other comprehensive income — detail
	439	748	201	—	—
	37.2	37.3	26.2	−117	35.8
	11.4	11.5	−3.3	—	—
	—	—	—	0.1	−5.4
	408	691	168	96.0	238
	−4.5	−30.7	−3.6	—	—
	—	—	—	7.8	−11.7
	—	—	204	−182	261
Per share — as-filed variants
	₹1.03	₹6.22	₹0.21	−₹9.79	−₹1.90
	₹1.03	₹6.22	₹0.21	−₹9.79	−₹1.90
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,477	2,523	2,210	2,019	1,902
	85.4%	86.1%	81.5%	77.2%	78.8%
Adjusted (ex-exceptional items) — derived
	17.9	109	37.4	−116	−6.4
	−2.8	−3.8	−18.1	−6.1	−48.2
	19.0	101	10.5	−147	−3.5
	₹1.21	₹6.45	₹0.68	−₹9.40	−₹0.22

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DCAL₹148.86

Dishman Carbogen Amcis Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersHIKAL SOLARA PANACEABIO INDSWFTLAB SAIPARENT INDOCO SMSPHARMA WINDLASMcap ₹2,334 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,412.9	2,615.8	2,711.5	2,931.9	2,901.5
Other Income	27.8	28.2	21.7	55.9	49.4
Total Income	2,440.7	2,644.0	2,733.2	2,987.8	2,950.8
Expenses
+ Cost of Materials Consumed	625.0	601.2	593.0	487.9	426.9
+ Changes in Inventories	-113.6	-4.0	-91.3	-79.1	-2.0
+ Employee Benefit Expense	1,035.3	1,208.2	1,293.6	1,446.9	1,484.1
+ Finance Costs	85.7	120.0	159.5	174.2	168.5
+ Depreciation & Amortisation	280.7	310.9	293.7	338.7	348.0
+ Other Expenses	534.0	523.9	447.3	510.6	507.4
Total Expenses	2,447.1	2,760.1	2,695.8	2,879.1	2,933.0
EBITDA	332.2	286.5	468.9	565.6	485.0
EBIT	51.5	-24.4	175.2	226.9	137.0
Profit
PBT before Exceptional Items	-6.4	-116.1	37.4	108.7	17.9
+ Exceptional Items	-48.2	-6.1	-18.1	-3.8	-2.8
Pretax Income	-54.6	-122.3	19.3	104.9	15.0
+ Current Tax	30.1	54.2	43.8	59.1	43.8
+ Deferred Tax	-54.9	-23.0	-27.7	-51.6	-44.9
Tax Expense	-24.8	31.2	16.1	7.5	-1.2
Net Income	-29.8	-153.5	3.2	97.5	16.2
+ Net Income — Continuing Ops	-29.8	-153.5	3.2	97.5	16.2
+ Other Comprehensive Income	290.5	-28.8	200.8	747.9	438.6
Total Comprehensive Income	260.7	-182.2	204.0	845.4	454.8
Net Income to Common	-29.8	-153.5	3.2	97.5	16.2
Per Share
Basic EPS	-1.90	-9.79	0.21	6.22	1.03
Diluted EPS	-1.90	-9.79	0.21	6.22	1.03
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	200.8	747.9	438.6
+ Items NOT to be Reclassified to P&L	35.8	-116.8	26.2	37.3	37.2
+ Tax on Items NOT to be Reclassified	—	—	-3.3	11.5	11.4
+ Tax on Items NOT to be Reclassified — alt tag	-5.4	0.1	—	—	—
+ Items to be Reclassified to P&L	237.6	96.0	167.8	691.3	408.3
+ Tax on Items to be Reclassified	—	—	-3.6	-30.7	-4.5
+ Tax on Items to be Reclassified — alt tag	-11.7	7.8	—	—	—
Comprehensive Income — Owners of Parent	260.7	-182.2	204.0	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-1.90	-9.79	0.21	6.22	1.03
Diluted EPS — Continuing Operations	-1.90	-9.79	0.21	6.22	1.03
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,901.5	2,018.6	2,209.9	2,523.1	2,476.6
Gross Margin %	78.81	77.17	81.50	86.06	85.35
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-6.4	-116.1	37.4	108.7	17.9
− Exceptional Items (reconciliation)	-48.2	-6.1	-18.1	-3.8	-2.8
Net Income Adj (tax-effected)	-3.5	-147.3	10.5	101.0	19.0
EPS Adj	-0.22	-9.40	0.68	6.45	1.21
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	0.00	0.00	0.36	0.42	0.48
Filed Dscr	3.00	2.00	2.05	1.25	1.33
Filed Iscr	5.00	3.00	3.12	3.43	3.47
Paid Up Equity Capital	31.4	31.4	31.4	31.4	31.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.